Cowen Appoints Lorence Kim as New Independent Board Director
Cowen Inc. (NASDAQ:COWN) has appointed Lorence Kim, M.D., to its Board of Directors, effective February 15, 2022, increasing the Board's size to nine members. Dr. Kim brings extensive experience in healthcare and finance, having served as CFO of Moderna, where he raised $4.4 billion. His background includes 14 years at Goldman Sachs and current roles on the boards of biotechnology firms. This strategic move aims to enhance Cowen's capabilities in executing its strategy and driving value for stakeholders.
- Appointment of Lorence Kim strengthens Board expertise in healthcare and finance.
- Dr. Kim's experience could provide valuable insights and strategic advantages.
- Potential concerns about Board continuity with new member integration.
NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Cowen Inc. (NASDAQ:COWN) (“Cowen” or the “Company”) is pleased to announce that Lorence Kim, M.D., has been appointed to its Board of Directors, effective February 15, 2022. The appointment will increase the size of Cowen’s Board to nine members.
“With his background in both health care and finance, Lorence is a tremendous addition to our Board,” said Jeffrey M. Solomon, Chair and Chief Executive Officer of Cowen. “As a well-respected member of the biotech community, Lorence brings his valuable operating experience and detailed understanding of a very important industry for us at Cowen. We look forward to his perspectives and expertise as we continue to execute on our strategy and drive value for Cowen’s stakeholders.”
Dr. Kim is currently a Venture Partner at Third Rock Ventures. Until June 2020, he served as Chief Financial Officer of Moderna, leading efforts to raise
Dr. Kim graduated magna cum laude from Harvard University with a bachelor’s degree in biochemical sciences. He earned an M.B.A. in healthcare management as a Palmer Scholar from the Wharton School of the University of Pennsylvania and an M.D. from the University of Pennsylvania School of Medicine.
Dr. Kim currently serves as a member of the Boards of Directors of Flare Therapeutics, a biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, and Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and inflammatory diseases, and on the Board of Governors of the American Red Cross. He previously served on the Board of Seres Therapeutics.
About Cowen Inc.
Cowen Inc. (“Cowen” or the “Company”) is a diversified financial services firm that operates through two business segments: a broker dealer and an investment management division. The Company’s broker dealer division offers investment banking services, equity and credit research, sales and trading, prime brokerage, global clearing, and commission management services. Cowen’s investment management segment offers actively managed alternative investment products. Cowen Inc. focuses on delivering value-added capabilities to our clients in order to help them outperform. Founded in 1918, the firm is headquartered in New York and has offices worldwide. Learn more at Cowen.com.
© 2022, COWEN INC., ALL RIGHTS RESERVED. COWEN AND COMPANY, LLC: MEMBER FINRA, NYSE AND SIPC
MEDIA CONTACT
Gagnier Communications
Dan Gagnier
dg@gagnierfc.com
646 569 5897
FAQ
Who is the newest member of Cowen's Board of Directors?
What is Lorence Kim's background?
When was Lorence Kim appointed to Cowen's Board?
How might Dr. Kim's appointment impact Cowen's strategy?
